ABBV vs PFE: pharma stock comparison

What happened: Pfizer and Bristol Myers Squibb (BMY) have been underperforming broad markets in recent years. AbbVie, however, has been aggressively expanding its pipeline, particularly in immunology and oncology, driving $61.2 billion in annual revenue. Pfizer, on the other hand, is diversifying its revenue stream through acquisitions to combat upcoming patent expirations. Both companies are actively working to navigate patent cliffs.

Market impact: The pharmaceutical sector is affected, with investors evaluating the long-term growth prospects of these companies. AbbVie's strong pipeline and Pfizer's acquisition strategy are reshaping the competitive landscape. The valuations of BMY and PFE have been repriced due to their recent underperformance.

What to watch next: AbbVie's earnings report on February 15, 2023, will provide insights into its pipeline progress. Pfizer's earnings on February 1, 2023, will offer updates on its acquisition strategy. Additionally, regulatory decisions on Pfizer's upcoming patent expirations will significantly impact its future revenue streams.